Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
79.91M | 65.42M | 45.52M | 45.18M | 41.14M | Gross Profit |
59.09M | 48.12M | 32.49M | 33.44M | 30.27M | EBIT |
-21.67M | -27.17M | -40.79M | -23.74M | -13.05M | EBITDA |
-16.57M | -22.83M | -36.57M | -28.37M | -12.48M | Net Income Common Stockholders |
-27.14M | -32.96M | -53.37M | -38.11M | -35.98M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
52.76M | 66.45M | 77.41M | 115.58M | 38.08M | Total Assets |
94.65M | 107.65M | 114.11M | 133.56M | 55.95M | Total Debt |
73.34M | 72.39M | 69.77M | 49.85M | 52.86M | Net Debt |
59.91M | 54.34M | 63.16M | 30.66M | 26.47M | Total Liabilities |
86.63M | 87.00M | 79.33M | 60.06M | 203.78M | Stockholders Equity |
8.01M | 20.65M | 34.78M | 73.50M | -147.83M |
Cash Flow | Free Cash Flow | |||
-17.95M | -19.87M | -37.47M | -24.96M | -21.67M | Operating Cash Flow |
-17.95M | -19.70M | -36.87M | -24.58M | -21.61M | Investing Cash Flow |
8.99M | 23.03M | 23.80M | -85.40M | -10.77M | Financing Cash Flow |
4.33M | 8.13M | 490.00K | 102.53M | 55.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $80.91M | 44.77 | 3.46% | ― | 24.75% | -61.29% | |
61 Neutral | $393.73M | ― | -76.21% | ― | 23.22% | 9.54% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
52 Neutral | $171.04M | ― | -76.01% | ― | 25.62% | 11.86% | |
50 Neutral | $431.30M | ― | -128.49% | ― | 22.05% | 29.86% | |
49 Neutral | $397.44M | ― | -161.19% | ― | 1.64% | 16.02% | |
46 Neutral | $352.60M | ― | -30.11% | ― | 15.32% | 15.73% |
On June 4, 2025, NeuroPace, Inc. entered into a $75 million credit facility with MidCap Financial, comprising a $60 million term loan and a $15 million revolving credit facility. This new financing arrangement allowed NeuroPace to repay its existing loan with CRG Partners IV, L.P., and the revolving credit will support working capital and corporate purposes. The favorable terms of the new credit facility are expected to reduce cash interest expenses and support NeuroPace’s growth initiatives, including expanding access to the RNS System and investing in new product developments.
The most recent analyst rating on (NPCE) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on NeuroPace stock, see the NPCE Stock Forecast page.
On May 27, 2025, NeuroPace announced the preliminary one-year results of its NAUTILUS study, which evaluates the safety and effectiveness of the RNS System for treating drug-resistant idiopathic generalized epilepsy. The study met its primary safety endpoint and showed significant seizure reduction in a key patient subgroup, suggesting potential benefits for a substantial portion of patients. NeuroPace plans to engage with the FDA regarding regulatory pathways and is confident in its long-term growth strategy, reaffirming its 2025 financial guidance.
The most recent analyst rating on (NPCE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on NeuroPace stock, see the NPCE Stock Forecast page.
On April 14, 2025, NeuroPace announced that it expects minimal impact from international trade tariffs on its operations and financial results, reaffirming its gross margin guidance for 2025. The company, which primarily manufactures and sells its devices in the U.S., anticipates no significant effect on its gross margin despite terminating its SEEG distribution agreement with DIXI Medical effective October 1, 2025. NeuroPace will report its first quarter 2025 financial results on May 13, 2025, with a conference call scheduled for the same day.
On April 2, 2025, NeuroPace, Inc. announced a strategic shift in its product portfolio, focusing on its core RNS System and ending its distribution agreement with DIXI Medical USA Corp. for SEEG products by September 30, 2025. This move is part of a broader plan to concentrate resources on expanding opportunities for the RNS System, including new indications and AI-enabled software, while maintaining 2025 revenue guidance and aiming for cash flow breakeven by 2027.